Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Rosuvastatin risks not apparent in database studies

    • 11 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Garciá-Rodríguez LA, Massó-González EL, Wallander M-A, Johansson S.The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care. Pharmacoepidemiology and Drug Safety 17: 943-952, No. 10, Oct 2008

    2. 2.

      García-Rodríguez LA, González-Pérez A, Stang MR, Wallander M-A, Johansson S.The safety of rosuvastatin in comparison with other statins in over 25 000 statin users in the Saskatchewan health databases. Pharmacoepidemiology and Drug Safety 17: 953-961, No. 10, Oct 2008

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Rosuvastatin risks not apparent in database studies. React. Wkly. 1228, 1 (2008). https://doi.org/10.2165/00128415-200812280-00001

    Download citation

    Keywords

    • Relative Risk
    • Statin
    • Acute Renal Failure
    • Myopathy
    • Rosuvastatin